Biomimetic Diselenide‐Sonosensitizer Nanoplatform for Enhanced Sonodynamic Therapy and In Situ Remodeling Immunosuppressive Microenvironment via Activating Innate and Adaptive Immunotherapy
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202403998 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Yifan Xue und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Engineering, Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong, 518107, China. Hauptthemen laut MEDLINE: Immunotherapy, Tumor Microenvironment, Immunity, Innate, Biomimetic Materials. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Guangdong Province, Shenzhen Science and Technology Project.
Abstract (Originalsprache)
Sonodynamic therapy (SDT), which is non‐invasive and controllable has the potential to treat triple‐negative breast cancer (TNBC). However, the hypoxia and immunosuppressive tumor microenvironment (TME) often block the production of reactive oxygen species and the induction of SDT‐activated immunogenic cell death, thus limiting the activation of adaptive immune responses. To alleviate these challenges, we proposed the development of a multifunctional biomimetic nanoplatform (mTSeIR), which was designed with diselenide‐conjugated sonosensitizers and tirapazamine (TPZ), encapsulated within M1 macrophage membrane. This nanoplatform utilized hypoxia‐induced chemotherapy to improve the efficacy of SDT, to further enhance adaptive immunotherapy by activating innate immunity and remodeling the immunosuppressive TME. Firstly, the prodrug TPZ was activated due to the increased oxygen consumption associated with SDT. Subsequently, the mTSeIR enhanced repolarization of M2 macrophages to the M1 phenotype. The diselenide component in mTSeIR effectively activated the natural killer cell‐mediated antitumor innate immune response. Ultimately, in vivo studies indicated that mTSeIR+US with good biosafety achieved over 98% tumor inhibition and enhanced adaptive immunotherapy. This research presents an efficient approach that addressed the limitations of SDT and achieves simultaneous activation of both innate and adaptive immunotherapy, resulting in significant antitumor and anti‐metastatic efficacy in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedical Engineering, Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong, 518107, China.
- Department of Hepatobiliary-Pancreatic-Splenic Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510630, China.
- Zhejiang Provincial Key Laboratory for Advanced Drug Delivery Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
ORCID-Profile: Jie Liu
Förderung
- National Key Research and Development Program of China
- Natural Science Foundation of Guangdong Province
- Shenzhen Science and Technology Project
Zitieren
APA
Xue, Y., Wang, Q., Chen, Y., Zhang, X., Tang, J., Liu, Y., & Liu, J. (2025). Biomimetic Diselenide‐Sonosensitizer Nanoplatform for Enhanced Sonodynamic Therapy and In Situ Remodeling Immunosuppressive Microenvironment via Activating Innate and Adaptive Immunotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202403998
Vancouver
Xue Y, Wang Q, Chen Y, Zhang X, Tang J, Liu Y, et al. Biomimetic Diselenide‐Sonosensitizer Nanoplatform for Enhanced Sonodynamic Therapy and In Situ Remodeling Immunosuppressive Microenvironment via Activating Innate and Adaptive Immunotherapy. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202403998
BibTeX
@article{Xue2025,
author = {Xue, Yifan and Wang, Qingliang and Chen, You and Zhang, Xiaoge and Tang, Junjie and Liu, Yadong and Liu, Jie},
title = {Biomimetic Diselenide‐Sonosensitizer Nanoplatform for Enhanced Sonodynamic Therapy and In Situ Remodeling Immunosuppressive Microenvironment via Activating Innate and Adaptive Immunotherapy},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202403998}
}
EUVIMED